JD.com, Inc. operates as a supply chain-based technology and service provider in the People's Republic of China. The company offers computers, communication, and consumer electronics products, as well as home appliances; and general merchandise products comprising food, beverage and fresh produce, baby and maternity products, furniture and household goods, cosmetics and other personal care items, pharmaceutical and healthcare products, industrial products, books, automobile accessories, apparel and footwear, bags, and jewelry. It also provides online marketplace services for third-party merchants; marketing services; and omni-channel solutions to customers and offline retailers, as well as online healthcare services. In addition, the company develops, owns, and manages its logistics facilities and other real estate properties to support third parties; offers asset management services and integrated service platform; leasing of storage facilities and related management services; and engages in online retail business. Further, it provides integrated data, technology, business, and user management industry solutions to support the digitization of enterprises and institutions; and technology-driven supply chain solutions and logistics services. The company was formerly known as 360buy Jingdong Inc. and changed its name to JD.com, Inc. in January 2014. JD.com, Inc. was incorporated in 2006 and is headquartered in Beijing, the People's Republic of China.

JD.com, Inc.

U.S. stocks finished a strong week with another rally on Friday after a surprisingly weak jobs report pushed investors to rethink the path for inte...

The Week That Was, The Week Ahead: Macro and Markets, August 9

An announcement from Judges Scientific ( ($GB:JDG) ) is now available. Judges Scientific has reported a series of director and senior management sh...

Judges Scientific Executives Receive Shares Under Incentive Plan

In a report released today, Ciaran Donnelly from Citi reiterated a Hold rating on Rightmove, with a price target of p486.00. According to TipRanks,...

Citi Sticks to Its Hold Rating for Rightmove (RMV)

Rightmove Plc (UK) (($GB:RMV)) has held its Q2 earnings call. Read on for the main highlights of the call. Rightmove Plc’s latest earnings call str...

Rightmove Plc Earnings Call: ARPA, AI And Headwinds

The latest announcement is out from Universal ( ($UVV) ). On July 29, 2026, Universal Corporation announced that J. Patrick O’Keefe intends to reti...

Universal Announces Leadership Transition in Ingredients Segment

In a report released yesterday, Anthony Codling from RBC Capital maintained a Buy rating on Rightmove, with a price target of p675.00. Codling cove...

RBC Capital Keeps Their Buy Rating on Rightmove (RMV)

In a report released today, Soundarya Iyer from B. Riley Securities initiated coverage with a Buy rating on Endeavour Silver and a price target of ...

Endeavour Silver (EXK) Has a New Rating from B. Riley Securities

Rightmove ( ($GB:RMV) ) has provided an update. Rightmove has updated the market on its capital structure, confirming that as of 31 July 2026 it ha...

Rightmove Updates Market on Total Voting Rights

J D Wetherspoon ( ($GB:JDW) ) has shared an announcement. J D Wetherspoon plc, a major U.K. pub and hospitality chain, operates a wide network of p...

Wetherspoon Confirms Total Voting Rights After Share Capital Update

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on Ionis Pharmaceuticals today and set a price target of $68.00. According to TipRank...

Ionis Pharmaceuticals (IONS) Receives a Hold from Stifel Nicolaus

Endeavour Silver (($TSE:EDR)) has held its Q2 earnings call. Read on for the main highlights of the call. Endeavour Silver’s latest earnings call s...

Endeavour Silver Earnings Call Highlights Growth Momentum

Rightmove ( ($GB:RMV) ) has provided an update. Rightmove plc has continued its long-running share buy-back programme with the repurchase of 114,40...

Rightmove Continues Long-Running Share Buy-Back Programme

In a report released today, Cosmos Chiu from CIBC maintained a Buy rating on Endeavour Silver, with a price target of C$25.00. According to TipRank...

Endeavour Silver (EXK) Gets a Buy from CIBC

Endeavour Silver ( ($TSE:EDR) ) just unveiled an update. Endeavour Silver Corp. is a Vancouver-based precious metals producer focused on undergroun...

Endeavour Silver Posts Surging Q2 2026 Profits on Higher Output and Prices

Precise Biometrics AB ( ($SE:PREC) ) just unveiled an announcement. Precise Biometrics CEO Joakim Nydemark has been interviewed in Dagens Industri’...

Precise Biometrics CEO Highlights Merger Strategy and Rights Issue in Dagens Industri Podcast

Rightmove ( ($GB:RMV) ) has shared an announcement. Rightmove plc has continued its long-running capital return strategy by repurchasing 102,000 or...

Rightmove Continues Long-Running Share Buy-Back as It Cancels New Batch of Shares

Valbiotis SA ( ($FR:ALVAL) ) has provided an announcement. Valbiotis is positioning itself as a specialist in preventive cardiometabolic solutions,...

Valbiotis Backs France’s Cardiovascular Prevention Push

Rightmove ( ($GB:RMV) ) has shared an announcement. Rightmove plc has continued its long-running share buy-back strategy, repurchasing 150,000 ordi...

Rightmove Extends Long-Running Share Buy-Back Programme

J D Wetherspoon ( ($GB:JDW) ) has issued an announcement. J D Wetherspoon has issued a detailed rebuttal to a Financial Times article suggesting th...

Wetherspoon Rebuts FT Claims on Gambling Machine Profits

The latest announcement is out from Rightmove ( ($GB:RMV) ). Rightmove plc has continued to execute its long-running share buy-back strategy, purch...

Rightmove Extends Long-Running Share Buy-Back with Fresh 150,000-Share Purchase

Morgan Stanley analyst Michael Ulz maintained a Buy rating on Ionis Pharmaceuticals today and set a price target of $110.00. According to TipRanks,...

Morgan Stanley Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

Berenberg Bank analyst reiterated a Buy rating on Judges Scientific today and set a price target of p5,600.00. Currently, the analyst consensus on ...

Judges Scientific (JDG) Receives a Buy from Berenberg Bank

In a report released yesterday, from Shore Capital reiterated a Hold rating on J D Wetherspoon. The company’s shares closed yesterday at p722.50. T...

Shore Capital Sticks to Their Hold Rating for J D Wetherspoon (JDW)

Barclays analyst Richard Taylor maintained a Sell rating on J D Wetherspoon today and set a price target of £5.40. According to TipRanks, Taylor is...

J D Wetherspoon (JDW) Receives a Sell from Barclays

The latest announcement is out from Bluejay Diagnostics ( ($BJDX) ). On July 21, 2026, Bluejay Diagnostics announced it had completed patient enrol...

Bluejay Diagnostics Completes Enrollment in SYMON-II Sepsis Study

J D Wetherspoon ( ($GB:JDW) ) has shared an update. J D Wetherspoon has issued a corrected pre-close trading update, confirming that like-for-like ...

Wetherspoon warns on profits despite sales growth and estate investment

In a report released yesterday, from CSC Financial maintained a Buy rating on JD.com, Inc. Class A, with a price target of HK$157.49. JD.com, Inc. ...

CSC Financial Sticks to Their Buy Rating for JD.com, Inc. Class A (9618)

An announcement from Precise Biometrics AB ( ($SE:PREC) ) is now available. Precise Biometrics has resolved to carry out a rights issue of up to 13...

Precise Biometrics Launches SEK 110m Rights Issue to Fund Integration After Fingerprint Cards Merger

Rightmove ( ($GB:RMV) ) just unveiled an update. Rightmove plc has continued to execute its long-running share buy-back strategy, repurchasing 150,...

The latest update is out from Judges Scientific ( ($GB:JDG) ). Judges Scientific has disclosed that Chief Financial Officer Brad Ormsby, together w...

Judges Scientific Executives Reinvest Dividends into Company Shares

An update from Precise Biometrics AB ( ($SE:PREC) ) is now available. Precise Biometrics has completed its statutory merger with Fingerprint Cards,...

Precise Biometrics Completes Merger with Fingerprint Cards to Form Global Biometric Player

Just days after warning that “the end is nigh” for the AI trade, famed investor Michael Burry is pointing investors toward a different corner of th...

It’s ‘a Particularly Good Time’ to Buy These Beaten-Down Chinese Tech Stocks, Says Michael Burry

GF Securities analyst maintained a Buy rating on JD.com, Inc. Class A yesterday and set a price target of HK$149.21. Currently, the analyst consens...

GF Securities Reaffirms Their Buy Rating on JD.com, Inc. Class A (9618)

Guotai Haitong analyst maintained a Buy rating on JD.com, Inc. Class A on July 15 and set a price target of HK$136.50. The company’s shares closed ...

Guotai Haitong Remains a Buy on JD.com, Inc. Class A (9618)

In a report released on July 15, from CLSA maintained a Buy rating on JD.com, Inc. Class A, with a price target of HK$150.15. The company’s shares ...

JD.com, Inc. Class A (9618) Receives a Buy from CLSA

An update from Rightmove ( ($GB:RMV) ) is now available. Rightmove plc has continued its longstanding share buy-back strategy, repurchasing 150,000...

Rightmove Continues Long-Running Share Buy-Back With New 150,000-Share Purchase

The latest announcement is out from J D Wetherspoon ( ($GB:JDW) ). J D Wetherspoon has disclosed a series of small share purchases by senior execut...

Wetherspoon directors add shares under employee partnership plan

In a report released yesterday, from CSC Financial maintained a Buy rating on JD.com, Inc. Class A, with a price target of HK$157.49. The word on T...

CSC Financial Sticks to Its Buy Rating for JD.com, Inc. Class A (9618)

CICC analyst maintained a Buy rating on JD.com, Inc. Class A on July 14 and set a price target of HK$140.40. In a report released yesterday, DBS al...

JD.com, Inc. Class A (9618) Receives a Buy from CICC

In a report released on July 14, from CMB International Securities maintained a Buy rating on JD.com, Inc. Class A, with a price target of HK$185.2...

CMB International Securities Remains a Buy on JD.com, Inc. Class A (9618)

In a report released yesterday, from UOB Kay Hian maintained a Buy rating on JD.com, Inc. Class A, with a price target of HK$156.00. Currently, the...

UOB Kay Hian Sticks to Their Buy Rating for JD.com, Inc. Class A (9618)

In a report released on July 13, from Daiwa maintained a Hold rating on JD.com, Inc. Class A, with a price target of HK$108.00. The company’s share...

Daiwa Sticks to Their Hold Rating for JD.com, Inc. Class A (9618)

In a report released today, Ben Wong from DBS maintained a Buy rating on JD.com, Inc. Class A, with a price target of HK$141.00. According to TipRa...

DBS Remains a Buy on JD.com, Inc. Class A (9618)

Rightmove ( ($GB:RMV) ) has issued an update. Rightmove plc has corrected a previous notice and confirmed it will publish its half-year results for...

Rightmove Confirms Correct Date for 2026 Half-Year Results

In a report released today, Jiong Shao from Barclays maintained a Buy rating on JD, with a price target of $41.00. According to TipRanks, Shao is a...

JD (JD) Gets a Buy from Barclays

In a report released yesterday, from China Merchants Securities maintained a Buy rating on JD.com, Inc. Class A, with a price target of HK$144.00. ...

China Merchants Securities Remains a Buy on JD.com, Inc. Class A (9618)

Huatai Securities analyst maintained a Buy rating on JD.com, Inc. Class A yesterday and set a price target of HK$152.09. In a report released on Ju...

Huatai Securities Sticks to Its Buy Rating for JD.com, Inc. Class A (9618)

Morgan Stanley analyst maintained a Sell rating on JD.com, Inc. Class A on July 13 and set a price target of HK$105.30. The company’s shares closed...

Morgan Stanley Keeps Their Sell Rating on JD.com, Inc. Class A (9618)

Nomura analyst maintained a Buy rating on JD.com, Inc. Class A on July 13 and set a price target of HK$159.90. The company’s shares closed yesterda...

Nomura Remains a Buy on JD.com, Inc. Class A (9618)

UBS analyst maintained a Buy rating on JD.com, Inc. Class A on July 13 and set a price target of HK$187.20. The company’s shares closed yesterday a...

JD.com, Inc. Class A (9618) Gets a Buy from UBS

Nvidia ($NVDA) and AMD ($AMD) shares moved higher on Tuesday after a Reuters report said three Chinese companies, including a unit of telecom equip...

Nvidia and AMD Stocks Rise on a Positive Shift in China’s AI Chips Scenario

The latest update is out from Rightmove ( ($GB:RMV) ). Rightmove has continued its long-running capital return strategy by purchasing 150,000 of it...

Rightmove Advances Long-Running Share Buyback Programme

In a report released today, Jessica Fye from J.P. Morgan maintained a Buy rating on Ionis Pharmaceuticals, with a price target of $72.00. According...

J.P. Morgan Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)

DBS analyst Ben Wong maintained a Buy rating on JD today and set a price target of $36.00. According to TipRanks, Wong is ranked #7449 out of 12329...

DBS Remains a Buy on JD (JD)

An announcement from Judo Capital Holdings Limited ( ($AU:JDO) ) is now available. Judo Capital Holdings Limited has notified the ASX of the cessat...

Judo Capital Updates Market on Lapse of Deferred Rights and Options

There’s a lot to be optimistic about in the Consumer Cyclical sector as 2 analysts just weighed in on JD (JD) and Ferrari (RACE) with bullish senti...

Analysts Offer Insights on Consumer Cyclical Companies: JD (JD) and Ferrari (RACE)

An update from Rightmove ( ($GB:RMV) ) is now available. Rightmove plc has continued executing its long-running share buy-back programme with the p...

Rightmove Cancels 150,000 Shares in Ongoing Buy-Back Programme

UBS analyst John Storey downgraded Judo Capital Holdings Limited to a Hold on July 10 and set a price target of A$1.10. The company’s shares closed...

Judo Capital Holdings Limited (JDO) was downgraded to a Hold Rating at UBS

Wells Fargo analyst maintained a Buy rating on Ionis Pharmaceuticals today and set a price target of $100.00. In addition to Wells Fargo, Ionis Pha...

Wells Fargo Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

In a report released today, Eliana Merle from Barclays maintained a Buy rating on Ionis Pharmaceuticals, with a price target of $90.00. According t...

Barclays Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals ( ($IONS) ) just unveiled an update. Ionis Pharmaceuticals and AstraZeneca reported on July 9, 2026, that the large Phase 3 C...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	JD	$32.97	+0.49%	4.20M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	JD	$32.97	+0.5%	4.20M
3
4
5
6

JD

JD

Get JD.com, Inc. Data in Excel

Get JD.com, Inc. Data in Excel